Solana Co — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Solana Co filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.02M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $520.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $644.0K | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $787.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $522.0K | Mar 9, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $548.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $520.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $605.0K | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $778.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $493.0K | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $661.0K | Mar 14, 2022 |
| FY2019 | Dec 31, 2019 | 500,000 | Mar 12, 2020 |
| FY2020 | Dec 31, 2019 | $1.50M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $478.0K | Mar 12, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.52M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($62.0K) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $61.0K | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $324.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $224.0K | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $273.0K | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $650.0K | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $478.0K | Mar 12, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($40.89M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($11.74M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($8.85M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($14.07M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($18.13M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($14.13M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($9.78M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($28.62M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($28.02M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($12.04M) | Mar 12, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($243.84M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($13.90M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($12.43M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($15.52M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($18.14M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($14.39M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($24.00M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($26.68M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($22.85M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($10.37M) | Mar 12, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.51M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.66M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.94M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $4.26M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $5.99M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $4.58M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $8.06M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $9.94M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $14.39M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $4.72M | Mar 12, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.13M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $10.18M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $9.27M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $10.64M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $12.18M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $9.71M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $16.52M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $17.21M | Mar 12, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.51M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($11.04M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($10.42M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($14.31M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($13.39M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($11.74M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($21.00M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($19.62M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($19.33M) | Mar 14, 2019 |
| FY2016 | Mar 31, 2016 | ($7.94M) | Jun 28, 2016 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $5.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $29.0K | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $17.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $54.0K | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $63.0K | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $278.0K | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $440.0K | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $190.0K | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Mar 12, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $303.93M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.54M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $7.69M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $17.29M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $14.10M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $6.55M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $10.35M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $27.83M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $6.81M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $3.45M | Mar 12, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.02M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.48M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.34M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $9.14M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $2.85M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $2.68M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $4.51M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $17.97M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $14.30M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $6.89M | Mar 12, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $300.91M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.06M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $2.35M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $8.15M | Mar 25, 2025 |
| FY2023 | Dec 31, 2021 | $11.26M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $3.87M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $5.84M | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | $9.85M | Mar 10, 2021 |
| FY2019 | Dec 31, 2017 | ($7.49M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | ($3.44M) | Mar 14, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $763.0K | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $759.0K | Mar 14, 2022 |
| FY2021 | Dec 31, 2019 | $1.24M | Mar 14, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($212.59M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($171.70M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($159.96M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($151.11M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($137.04M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($118.90M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($104.77M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($94.99M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($66.37M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($38.35M) | Mar 12, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.28M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.09M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.18M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $14.55M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $11.01M | Mar 9, 2023 |
| FY2016 | Mar 31, 2016 | $2.64M | Jun 28, 2016 |
| FY2016 | Mar 31, 2015 | $418.9K | Jun 28, 2016 |
| FY2016 | Mar 31, 2014 | $16.0K | Jun 28, 2016 |
| FY2015 | Mar 31, 2013 | $217 | Jan 11, 2016 |
| FY2015 | Mar 31, 2012 | $0 | Jan 11, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (3,282) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (14) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | (52) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (7) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | (11) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | (12) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | (1) | Mar 12, 2020 |
| FY2016 | Mar 31, 2016 | 0 | Jun 28, 2016 |
| FY2016 | Mar 31, 2015 | 0 | Jun 28, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (3,282) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (14) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | (52) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (7) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | (11) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | (12) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | (1) | Mar 12, 2020 |
| FY2016 | Mar 31, 2016 | 0 | Jun 28, 2016 |
| FY2016 | Mar 31, 2015 | 0 | Jun 28, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 43.74M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 4,936 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 714,590 | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 564,094 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 3.78M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 1.48M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | 877,672 | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | 25.83M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | 20.18M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | 16.93M | Mar 12, 2018 |